Anhydrous enol oxaloacetate is under clinical development by MetVital and currently in Phase II for Fatigue. According to GlobalData, Phase II drugs for Fatigue does not have sufficient historical ...

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

Central Pacific Bank Trust Division bought a new position in argenx SE (NASDAQ:ARGX – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

SPRINGFIELD, Ill. – The Illinois Department of Public Health (IDPH) has approved four new conditions for treatment with ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Ancient Viral DNA in the Human Genome Linked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis Oct. 21, 2024 — New research has revealed a connection between ancient viral DNA embedded in ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.